This pathway is thought to be CFTR dependent and thus defective in cystic fibrosis; however, the ionic mechanism that drives this secretion process is incompletely understood. To better define this mechanism, we studied the effects of ion transport inhibitors on the forskolin-induced liquid secretion response (Jv) of porcine distal bronchi. The forskolin-induced Jv was driven by a combination of bumetanide-sensitive Cl Ϫ secretion and DIDS-sensitive HCO 3 Ϫ secretion. When Cl Ϫ secretion was inhibited with bumetanide, Na ϩ /H ϩ exchange-dependent HCO 3 Ϫ secretion was apparently induced to compensate for the loss of Cl Ϫ secretion. The forskolin-induced Jv was significantly inhibited by the anion channel blockers 5-nitro-2-(3-phenylpropylamino)benzoic acid, diphenylamine-2-carboxylate, and glibenclamide. We conclude that the forskolininduced Jv shares many characteristics of cholinergically induced secretion except for the presence of a DIDS-sensitive component. Although the identity of the DIDS-sensitive component is unclear, we speculate that it represents a basolateral membrane Na ϩ -HCO 3 Ϫ cotransporter or an Na ϩ -dependent anion exchanger, which could account for transepithelial HCO 3 Ϫ secretion.
cystic fibrosis; airway liquid secretion; submucosal glands SUBMUCOSAL GLANDS OF THE TRACHEOBRONCHIAL airways secrete numerous macromolecular substances including the gel-forming mucins and antimicrobial peptides such as lysozyme. To flush these substances from the gland ducts as well as to adequately hydrate the mucus gel, ions and water are thought to be secreted by the serous cells located in the distal portions of the gland tubules (22) . In humans, pigs, and sheep, secretion of airway gland liquid is principally under muscarinic and peptidergic neural control (2); however, in cat and ferret airways, ␣-adrenergic stimulation is also capable of inducing significant liquid secretion (21, 23) . Although the ionic mechanism responsible for elaboration of this fluid remains to be fully defined, there is little doubt that gland liquid is largely generated through the active transepithelial secretion of anions (3, 29, 30) . Several lines of evidence suggests that the cystic fibrosis transmembrane conductance regulator (CFTR), a cAMP-activated anion channel, plays an integral role in the secretion of gland liquid. First, CFTR has been shown to be heavily expressed in the apical membrane of gland serous cells by immunohistochemistry and in situ hybridization (7, 11) , although these findings have been recently challenged (17) . Second, numerous pharmacological inhibitors of the CFTR have been shown to be efficacious inhibitors of gland liquid secretion (3, 28, 29) . Third, and most convincingly, airway submucosal glands from the lungs of human CF patients, who express genetically defective CFTR, lose the ability to respond to either vasoactive intestinal peptide (VIP) or forskolin, agents that induce secretion in normal airways by elevating intracellular levels of cAMP (13) . These findings suggest that a defect in liquid secretion from glands may underlie the complex pulmonary pathology of this disease, which includes production of abnormally thick inspissated mucus, impairment of mucociliary and cough clearance, and chronic airway infections. Unfortunately, the ionic mechanism that underlies cAMP-dependent liquid secretion from glands is not completely understood. The objective of the present study was therefore to better define the mechanism responsible for cAMP-activated ion and liquid transport pathways in airway glands.
METHODS

Experimental protocol.
The protocols for animal use were reviewed and approved by institutional animal care and use committees and complied with both UK and US governmental policies on humane care and use of laboratory animals. Young domestic pigs (ϳ10 -15 kg) were sedated with intramuscular xylazine (4 mg) and ketamine (80 mg) and killed with an intravenous overdose of pentobarbital sodium. The lung lobes were removed and placed in Krebs Ringer bicarbonate (KRB) at room temperature. Segments of intralobular bronchi (ϳ30 -40 mm in length) were dissected from the lung parenchyma, and the side branches of the airways were ligated with suture. Bronchi were slowly warmed to 37°C (ϳ0.1°C/min) in a KRB bath.
At the end of the warming period, the airways were exposed to a variety of pretreatments designed to inhibit specific transport processes. One or more of the following transport inhibitors were added to the KRB bath. Bumetanide (10 M), a loop diuretic that inhibits Na ϩ -K ϩ -2Cl Ϫ cotransport (NKCC), was used to block transepithelial Cl Ϫ secretion. Dimethylamiloride (DMA, 100 M), an inhibitor of Na ϩ /H ϩ exchange (NHE), was used to block extrusion of H ϩ across the basolateral membrane, a maneuver that effectively inhibits HCO 3 Ϫ secretion that is dependent on intracellular HCO 3 Ϫ generation (27). 4,4Ј-Diisothiocyanostilbene-2,2Ј-disulfonic acid (DIDS, 1 mM) was used as a potential inhibitor of Cl Ϫ / HCO 3 Ϫ exchange (AE), Na ϩ -nHCO 3 Ϫ cotransport (NBC), Na ϩ -dependent Cl Ϫ /HCO 3 Ϫ exchange (NDAE), or possibly non-CFTR anion channels. 5-Nitro-2-(3-phenylpropylamino)benzoic acid (NPPB, 300 M), diphenylamine-2-carboxylate (DPC, 1 mM), and glibenclamide (1 mM), which inhibit a number of different anion channels including CFTR (25) , were used as anion channel blockers. The effect of niflumic acid (1 mM), which has often been used to block Ca 2ϩ -activated anion channels (12, 15, 16) and recently shown to exhibit CFTR blocking activity as well (26) , was also assessed. Acetazolamide (10 mM) was used to inhibit carbonic anhydrase and thereby reduce HCO 3 Ϫ synthesis. In some experiments, the normal KRB bath solution was replaced with equal volumes of warm (37°C) Cl Ϫ -free KRB, HCO 3 Ϫ -free KRB, Na ϩ -free KRB, or Ca 2ϩ -free KRB. During this incubation period, the ends of the airways were open to the bath solution, and the inhibitors had access to both the luminal and adventitial sides of the tissues.
After a 45-min incubation period with the above pretreatments, the airways were removed from their bath solutions, and all accessible fluid and mucus was removed from their lumens. The bronchi were then tied with suture onto polyethylene cannulas and returned to their respective baths. Forskolin (10 M), a direct activator of adenylyl cyclase, was added to the bath to elevate intracellular cAMP and stimulate anion and liquid secretion. All inhibitor experiments were performed with paired control airways that were exposed to only forskolin and the inhibitor vehicle, dimethyl sulfoxide (DMSO).
After a 2-h incubation with forskolin, the bronchi were removed from their cannulas and sectioned lengthwise, and all accessible mucus liquid was recovered from the lumens. Mucus liquid was placed into tared tubes, sealed, and then weighed to determine secretion volume. This method was deemed appropriate to assess liquid flux since the nonvolatile solids content of the secreted liquid is unlikely to exceed 5% of the liquid weight under these conditions (31) . Liquid samples were frozen and stored at Ϫ70°C for later analysis. Airway lengths and outer diameters were measured and used to estimate luminal surface areas as previously described (30) . Net liquid secretion rates (J v) were calculated based on the total secretion volume, the luminal surface area, and the time of secretagogue exposure.
Removal of the surface epithelium. To determine whether the source of the secreted liquid was the surface epithelium or the submucosal glands, the surface epithelium of some airways was abrasively removed with a wooden ream, and the tissues were exposed to forskolin with and without a secretion inhibitor. The mucosal surface of selected airways was examined with a Zeiss ACM microscope equipped with a ϫ20 water immersion objective to confirm that this technique adequately removed the surface epithelium and left the submucosal structures intact.
Solution instillation. To assess the magnitude of possible temporal changes in HCO 3 Ϫ concentration in the luminal liquid due to diffusion or transport across the surface epithelium, solutions of varying HCO 3 Ϫ composition were instilled into the lumen of cannulated bronchi. These solutions consisted of either normal KRB (25 mM HCO 3 Ϫ ), 150 mM NaCl (HCO 3 Ϫ -free), or 150 mM NaHCO3. The submucosal bath was always normal KRB (25 mM HCO 3 Ϫ ). Otherwise, the airways were not exposed to any inhibitors, vehicle, or secretagogues. After 2-h incubation with the instillates, the airways were removed from the cannulas, and the residual luminal solutions were collected, frozen, and later assayed for HCO 3 Ϫ concentration. Bicarbonate analysis. Frozen samples were thawed, and HCO 3 Ϫ concentrations were determined with an Infinity CO2 kit (Sigma Chemical/Thermo Electron). Because the HCO 3 Ϫ concentrations in liquid from bumetanide-treated tissues were typically higher than control treatments, these samples were diluted to ensure that the concentrations would fall within the linear range of the assay.
Solution composition and drugs. Normal KRB contained 112.0 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 2.4 mM MgSO4, 1.2 mM KH2PO4, 25.0 mM NaHCO3, and 11.6 mM glucose. For Cl Ϫ -free KRB, NaCl and KCl were respectively replaced with equimolar Na-gluconate and K-gluconate. To compensate for the Ca 2ϩ chelating effects of gluconate ions, 4.5 mM Ca-gluconate was added to the solution (19) . For Na ϩ -free KRB, NaCl and NaHCO3 were respectively replaced with equimolar choline-Cl and choline-HCO3. To make Ca 2ϩ -free KRB, CaCl2 was omitted from the solution and 2.5 mM EGTA was added to chelate free Ca 2ϩ . For HCO 3 Ϫ -free KRB, NaHCO 3 was replaced with 25 mM HEPES buffer, and the solution was titrated to pH 7.4. High-HCO 3 Ϫ solution was composed of only 150 mM NaHCO3. When HCO 3 Ϫ -free KRB was used, the solution was gassed with 100% O2. Otherwise, the pH of all KRB solutions was maintained at 7.4 by constant gassing with 95% O2/5% CO2. NPPB was obtained from Calbiochem. DPC was purchased from Aldrich as N-phenylanthranillic acid. All other drugs were purchased from Sigma Chemical. Stock solutions of all inhibitors and forskolin were prepared with DMSO.
Statistics. Data are reported as means Ϯ SE. The number of bronchi in each group are represented by n with each tissue taken from a different animal. The only exception to this is when aggregate forskolin control statistics are reported for liquid secretion rates and HCO 3 Ϫ concentrations where responses from two control bronchi, used for comparing two different inhibitor treatments, were sometimes taken from the same animal. All inhibitor experiments were performed with paired control airways that were exposed to only the inhibitor vehicle and forskolin. Paired comparisons were made with a paired Student's t-test, and unpaired comparisons were made by ANOVA (SigmaStat software, version 2.0). P Ͻ 0.05 was considered significant. All statistical comparisons were made on the raw data. However, for clarity, much of the data are expressed in the figures as percentages of their respective control responses.
RESULTS
Aggregate control responses.
Previous studies demonstrated that cannulated porcine bronchi, in the absence of secretagogues, secrete little fluid (30) . In the present study, aggregate control bronchi secreted 5.4 Ϯ 0.2 l⅐cm Ϫ2 ⅐h Ϫ1 (n ϭ 127) when treated with forskolin. The concentration of HCO 3 Ϫ in the luminal liquid of forskolin-treated control bronchi was 18.8 Ϯ 0.6 meq/l (n ϭ 113).
Ion replacement. The J v response to forskolin was profoundly reduced when tissues were exposed to Na ϩ -free solution (6.8 Ϯ 1.8% of control, n ϭ 6), indicating that virtually all secretory processes were dependent upon extracellular Na ϩ (Fig. 1A) . The J v was significantly reduced by approximately one-half in tissues bathed in Cl Ϫ -free solution (46.9 Ϯ 7.2% of control, n ϭ 6) and HCO 3 Ϫ -free solution (56.3 Ϯ 14.6% of control, n ϭ 7), suggesting prominent requirements for these ions as well. Removal of Ca 2ϩ from the bath solution also significantly reduced the J v response (37.8 Ϯ 9.3% of control, n ϭ 7) in these tissues; thus Ca 2ϩ signaling likely plays an important role in the secretion response to forskolin.
Bicarbonate concentration in the secreted liquid was not different from control in Na ϩ -free treated airways (97.2 Ϯ 22.6% of control, n ϭ 5) but was significantly elevated in tissues exposed to Cl Ϫ -free solutions (166.6 Ϯ 18.2% of control, n ϭ 5) (Fig. 1B) . We speculate that these elevated HCO 3 Ϫ concentrations reflect the dependence of the residual secretion process on HCO 3 Ϫ transport under Cl Ϫ -free conditions. When airways were exposed to HCO 3 Ϫ -free solution, this anion was undetectable. In Ca 2ϩ -free solution, HCO 3 Ϫ concentrations were significantly reduced in secreted liquid (50.6 Ϯ 9.3%, n ϭ 5).
Anion channel blockers. The effects of a number of potential anion channel inhibitors were assessed on forskolin-induced secretion ( Fig. 2A) . The CFTR inhibitors NPPB, DPC, and glibenclamide all significantly reduced the J v response to forskolin [12.6 Ϯ 6.4% of control (n ϭ 12), 18.8 Ϯ 5.8% of control (n ϭ 8) and 37.1 Ϯ 10.3% of control (n ϭ 7), respectively]. Niflumic acid, a more potent inhibitor of Ca 2ϩ -activated anion channels than CFTR (26), had no significant effect on the forskolin-induced J V in these airways (86.1 Ϯ 11.8% of control, n ϭ 6). Inhibition of the J v by NPPB, DPC, and glibenclamide would be consistent with CFTR participation in forskolin-induced liquid secretion, whereas lack of a niflumic acid response would not. DIDS, which inhibits numerous non-CFTR anion channels as well as several anion transport proteins, significantly reduced the J v to 55.3 Ϯ 10.8% of control (n ϭ 6). A partial inhibitory effect of DIDS suggests that either an alternate anion channel or one of several possible anion exchangers and/or cotransporters participates in the secretion response. The HCO 3 Ϫ concentration in the secreted liquid was significantly lower than control in airways pretreated with NPPB (40.0 Ϯ 15.4% of control, n ϭ 5) and DIDS (50.4 Ϯ 6.8% of control, n ϭ 5) (Fig. 2B) . DPC (59.4 Ϯ 13.8% of control, n ϭ 4) and glibenclamide (74.6 Ϯ 16.8% of control, n ϭ 5) reduced HCO 3 Ϫ concentrations somewhat, but these changes were not statistically significant. The effects of these agents are consistent with inhibition of forskolin-induced HCO 3 Ϫ secretion. Niflumic acid had no appreciable effect on HCO 3 Ϫ concentration (97.6 Ϯ 31.9% of control, n ϭ 6).
Bicarbonate secretion inhibitors. We reasoned that intracellular HCO 3 Ϫ generation could be facilitated by carbonic anhydrase and removal of H ϩ from the cytoplasm by basolateral NHE. When acetazolamide, an inhibitor of carbonic anhydrase, was applied to the airways, no effect on forskolin-induced J v was seen (94.9 Ϯ 24.4% of control, n ϭ 5) (Fig. 3A) . Similarly, no significant effect on J v was seen with DMA, an inhibitor of NHE (75.9 Ϯ 11.2% of control, n ϭ 6). When DIDS was combined with DMA, J v was significantly inhibited to a similar level as seen with DIDS alone (60.5 Ϯ 9.4% of control, n ϭ 7). Taken alone, these data suggest that forskolin-induced volume secretion is insensitive to carbonic anhydrase or NHE inhibition.
Surprisingly, acetazolamide pretreatment significantly reduced the HCO 3 Ϫ concentration in secreted liquid (59.1 Ϯ 13.4% of control, n ϭ 5) (Fig. 3B ) even though it did not alter the J v . This finding suggests that acetazolamide did indeed reduce at least a fraction of HCO 3 Ϫ secretion but that secretion of another anion, most likely Cl Ϫ , was induced to compensate for this loss. DIDS, as discussed above, significantly reduced HCO 3 Ϫ concentration, whereas DMA pretreatment had no effect (109.8 Ϯ 12.6% of control, n ϭ 6). The combination of DMA and DIDS reduced the HCO 3 Ϫ concentration (72.1 Ϯ 12.0% of control, n ϭ 6), but this change was not significant.
Bumetanide and bicarbonate secretion inhibitors. Bumetanide had no significant effect on the forskolin-induced J v (84.6 Ϯ 13.7% of control, n ϭ 7) (Fig. 4A) . This was surprising given that about one-half of the J v was dependent on bath Cl Ϫ (see Fig. 1A ). A number of potential HCO 3 Ϫ secretion inhibitors were thus used in combination with bumetanide to determine whether the bumetanide-insensitive J v was due to secretion of this anion. Addition of either DMA or DIDS to the bumetanide pretreatment significantly reduced the forskolin-induced J v to 52.6 Ϯ 4.4% (n ϭ 6) and 52.0 Ϯ 5.9% (n ϭ 8) of their respective controls. The combination of bumetanide, DMA, and DIDS essentially abolished the J v response to forskolin (8.6 Ϯ 2.8% of control, n ϭ 6), as did bumetanide in HCO 3 Ϫ -free solution (11.7 Ϯ 2.6% of control, n ϭ 6). Although it had no effect of its own on the forskolin-induced J v (see Fig. 3A ), acetazolamide substantially reduced the J v to 24.0 Ϯ 6.6% of control (n ϭ 7) in the presence of bumetanide (Fig. 4A) .
Accordingly, DMA-inhibitable HCO 3 Ϫ secretion appeared to have been induced by bumetanide since no significant effect of DMA was seen in the absence of this loop diuretic. The fractional inhibitory effects of DIDS on HCO 3 Ϫ secretion persist in the presence of bumetanide such that the combination of bumetanide, DMA, and DIDS inhibits virtually all of the forskolin-induced J v . Abolition of the J v by acetazolamide in the presence but not absence of bumetanide supports our speculation (see Bicarbonate secretion inhibitors) that carbonic anhydrase inhibition by itself induces Cl Ϫ secretion in these tissues. Furthermore, the observation that Cl Ϫ -free solution blocks nearly all of the J v in the presence of DIDS (21.9 Ϯ 2.7% of control, n ϭ 6) (Fig. 4A) substantiates the notion that the DMA-sensitive component of the Jv is inducible by bumetanide, whereas the DIDS-sensitive component is not.
The concentration of HCO 3 Ϫ in the secreted liquid from airways pretreated with only bumetanide was substantially increased (238.7 Ϯ 34.0% of control, n ϭ 6) (Fig. 4B) . When one considers that very little change in J v accompanied bumetanide pretreatment, these data further indicate that HCO 3 Ϫ secretion was induced by this agent to compensate for the inhibition of NKCC-dependent Cl Ϫ secretion. Addition of either DMA or DIDS blocked approximately one-half of the bumetanide-induced increase in HCO 3 Ϫ concentration to 165.2 Ϯ 15.7% of control (n ϭ 6) and 168.6 Ϯ 29.5% of control (n ϭ 8), respectively. When bumetanide, DMA, and DIDS were combined as a pretreatment, HCO 3 Ϫ concentration was reduced to control levels (98.9 Ϯ 9.7% of control, n ϭ 5). Similarly, acetazolamide also reduced the bumetanide-induced increase in HCO 3 Ϫ concentration to control levels (107.3 Ϯ 18.5% of control, n ϭ 6). Bicarbonate was undetectable in the liquid from airways treated with bumetanide and HCO 3 Ϫ -free solution. Bicarbonate concentrations were unaffected in liquid from airways treated with Cl Ϫ -free solution and DIDS (106.8 Ϯ 23.8% of control, n ϭ 5). Because DMA reduced both J v and HCO 3 Ϫ concentration only in the presence of bumetanide, it is most likely that inhibition of NKCC with this diuretic induced HCO 3 Ϫ secretion that was dependent on NHE. Removal of the surface epithelium. To localize the site of forskolin-induced liquid secretion, forskolin was applied to some airways whose surface epithelium was abrasively removed leaving the submucosal glands intact. Epithelium removal had no significant effect on the J v response to forskolin or to its inhibition by NPPB (Fig. 5) . Consequently, the liquid secretion response to forskolin was likely to have originated from submucosal glands.
Bicarbonate instillates. If all of the bumetanide-insensitive J v was due to HCO 3 Ϫ secretion, we expected the HCO 3 Ϫ concentration in airway liquid to approach that of isosmotic NaHCO 3 (i.e., ϳ150 mM). However, in the tissues pretreated with bumetanide, the HCO 3 Ϫ concentration in the secreted liquid was not higher than 41.9 meq/l. We reasoned that high concentrations of HCO 3 Ϫ may not have been sustainable across the surface epithelium because of the potential for this anion to leak across the tight junctions into the submucosal bath where the concentration was 25 mM. To test this notion, the lumen of the airways was filled with solutions containing various HCO 3 Ϫ concentrations while the bath contained normal 25 mM HCO 3 Ϫ KRB. After 2 h, the HCO 3 Ϫ concentration in the instillates that had initially contained 150 mM HCO 3 Ϫ had fallen to 54.3 Ϯ 6.7 meq/l (n ϭ 6) (Fig. 6 ). When the instillates were initially HCO 3 Ϫ -free, the HCO 3 Ϫ concentration rose to nearly that of the KRB bath (18.3 Ϯ 2.6 meq/l, n ϭ 6) after 2 h. When the instillates were normal KRB (identical to the bath), the HCO 3 Ϫ concentration in the instillate was 22.1 Ϯ 2.2 meq/l (n ϭ 6). It was thus likely that some magnitude of HCO 3 Ϫ equilibration occurred between the secreted luminal liquid and the KRB bath during the course of the experiments.
DISCUSSION
In this study of ion and liquid secretion by porcine bronchi, we found that the J v response to forskolin is driven by a combination of transepithelial Cl Ϫ and HCO 3 Ϫ secretion. The Cl Ϫ fraction of liquid secretion appears to be sensitive to bumetanide, indicating that the nonrenal isoform of the Na ϩ -K ϩ -2Cl Ϫ cotransporter, NKCC1, mediates this process. The HCO 3 Ϫ fraction of the J v appears to be dependent on two distinct processes that are defined by the inhibitors that block these pathways. One pathway is sensitive to the disulfonic stilbene inhibitor DIDS, which is known to block several potential HCO 3 Ϫ transporters. The other pathway, which appears to be induced following bumetanide treatment, is sensitive to the NHE inhibitor DMA. Sensitivity of the J v response to anion channel blockers suggests that anion channels are present for conducting Cl Ϫ and HCO 3 Ϫ efflux across the apical membrane of secretory cells. Because the J v response persists following removal of the surface epithelium, we conclude that the secreted liquid originates from the submucosal glands. Our findings and interpretations of these data, as detailed in this discussion, are summarized in the model shown in Fig. 7 .
It was not immediately apparent to us that the forskolininduced J v was fractionally supported by NKCC-mediated Cl Ϫ secretion, since no significant reduction in J v occurred when tissues were treated with bumetanide. However, we observed that the application of bumetanide was accompanied by an approximate 140% increase in the HCO 3 Ϫ concentration in the secreted fluid, suggesting that net HCO 3 Ϫ secretion was induced in the presence of this inhibitor. Similar induction of HCO 3 Ϫ secretion has been described in a previous study of isolated porcine bronchi (10) . We also noted that DMA, which inhibits Ϫ in all experiments. After 2 h, the luminal fluid was collected, and the final HCO 3 Ϫ concentrations were measured (y-axis). Note that substantial changes occurred in the HCO 3 Ϫ concentration of luminal liquid that were consistent with partial equilibration with the bath solution.
the fraction of HCO 3 Ϫ secretion that is dependent on H ϩ extrusion across the basolateral membrane through NHE, significantly inhibited the J v but only in the presence of bumetanide. This finding suggests that DMA-dependent HCO 3 Ϫ secretion is induced by bumetanide and that the magnitude of this fraction of HCO 3 Ϫ secretion is sufficient to compensate in large part for the reduction in Cl Ϫ secretion. Confirmation that the airways secrete Cl Ϫ was seen when the J v was reduced ϳ50% by exposure to Cl Ϫ -free solution. However, induction of HCO 3 Ϫ secretion by Cl Ϫ -free solution, as judged by the liquid secretion response and the increase in HCO 3 Ϫ concentration, must have been much weaker than that seen with bumetanide. We cannot presently account for this discrepancy since both bumetanide and Cl Ϫ -free treatments should reduce Na ϩ , K ϩ , and Cl Ϫ influx across the basolateral membrane through NKCC. We speculate that the stimulus for both NKCC and NHE activation is cell shrinkage, which likely occurs immediately following stimulation (8) . Perhaps pharmacological blockade of NKCC leads to an exaggerated cell shrinkage response that maximizes NHE activity. Extracellular Cl Ϫ -free solution does not simply block influx of these ions across the basolateral membrane of these cells; this maneuver should reverse the net driving force so that ion efflux through NKCC is favored, a condition that might somehow minimize or prevent NHE induction. Alternatively, if the anion exchanger AE2 is present in the basolateral membrane as reported for Calu-3 cells and rat tracheal serous cells (18) , it is possible that extracellular Cl Ϫ -free solution could drive significant influx of HCO 3 Ϫ through this anion exchanger, thus alkalinizing the cytoplasm sufficiently to prevent activation of NHE. It is worthy of note that Joo and coworkers (14), who measured forskolin-and carbachol-induced liquid secretion from individual glands in porcine tracheae, report no evidence of HCO 3 Ϫ secretion induction with either bumetanide or Cl Ϫ -free solution. We are currently unable to account for this discrepancy; however, we are confident in our observation since we have seen evidence of bumetanide induction of HCO 3 Ϫ secretion in our prior studies of both acetylcholine-and substance Pinduced secretion in porcine bronchi (2, 10, 29, 30) .
Our results indicate that DIDS most likely reduced the J v response to forskolin by inhibiting a component of HCO 3 Ϫ secretion. This notion is evidenced by the parallel fall in HCO 3 Ϫ concentration in the secreted liquid and the apparent sensitivity of the DIDS component to HCO 3 Ϫ removal in the presence of bumetanide. It is unclear, however, which ion transporter was targeted by DIDS to induce this effect. DIDS is known to inhibit AE (24) . Recycling Cl Ϫ across the basolateral membrane through NKCC and AE2 could theoretically drive transepithelial HCO 3 Ϫ secretion through this anion exchanger; however, according to this mechanism, DIDS-sensitive HCO 3 Ϫ secretion should be dependent on NKCC activity and thus inhibited by bumetanide, which does not appear to be the case from our data. Moreover, the stoichiometry of these anion exchangers is 1:1; therefore, no net charge or net osmolyte transfer should be achieved by anion exchange activity alone across either the apical or basolateral membranes. DIDS is also known to inhibit NBC and NDAE transporters (24) , which could drive HCO 3 Ϫ entry across the basolateral membrane of secretory cells. Involvement of either of these transporters is more likely since they could account for the extracellular Na ϩ dependence of this component of the forskolin-induced J v . In support of our findings, Devor and coworkers (6) observed in Calu-3 cells that forskolin induced HCO 3 Ϫ secretion that appeared to be driven by a basolateral membrane NBC cotransporter in that this process was Na ϩ dependent and inhibited by a related stilbene inhibitor, 4,4Ј-dinitrostilbene-2,2Ј-disulfonic acid. Furthermore, mRNA for NBC1 has been identified in Calu-3 cells (9) , and this transporter has been shown to be activated by cAMP in porcine vas deferens (4) as well as murine colonic crypts (1). However, in contrast to our findings from the present study, forskolin alone apparently does not induce bumetanide-sensitive Cl Ϫ -secretion in Calu-3 cells (4). Because of the lack of selectivity of these anion channel blockers, it is not possible to identify the specific anion channel(s) involved by the secretion response to any single inhibitor. However, the responses to a spectrum of inhibitors and agonists can provide important clues as to the channels that most likely participate in the secretion process of glands. In the present study, NPPB, DPC, and glibenclamide significantly reduced the forskolin-induced J v . These agents have been all been recognized as inhibitors of CFTR though their selectivity among different classes of anion channels is poor (25) . Niflumic acid, which is often used as a probe of Ca 2ϩ -activated Cl Ϫ channels, had no effect on forskolin-induced secretion in the present study. Although niflumic acid is capable of blocking CFTR, it is more potent against Ca 2ϩ -activated Cl Ϫ channels and is a less potent blocker of CFTR than NPPB (26) . CFTR is activated when phosphorylated by protein kinase A (5); consequently, forskolin, which increases cAMP production through direct stimulation of adenylyl cyclase, is often used as a probe of CFTR activity. The endogenous agonist for CFTRdependent secretion in normal airway glands is probably VIP, since submucosal glands from human CF airways lose the Ϫ is driven across the basolateral membrane through NKCC1 (1) and exits the cell through CFTR (2) . HCO 3 Ϫ is transported across the basolateral membrane through an Na ϩ -nHCO 3 Ϫ cotransporter (3), or perhaps an Na ϩ -dependent Cl Ϫ HCO 3 Ϫ exchange, and exits the cell through CFTR (2) . In the presence of bumetanide, a second HCO 3 Ϫ secretory pathway is induced. In this pathway, carbonic anhydrase (CA) generates intracellular HCO 3 Ϫ along with H ϩ , which must be extruded across the basolateral membrane through an Na ϩ /H ϩ exchange (4). HCO 3 Ϫ then exits the cell through CFTR (2) . See the text for details and discussion of these pathways.
ability to respond to either forskolin or VIP (13) . Although our results are not definitive, the aggregate data support a role for CFTR in the forskolin-induced J v . We cannot discount the possibility that DIDS, which blocks numerous non-CFTR anion channels, reduces a component of the J v through blockade of a non-CFTR, cAMP-regulated anion channel. But, aside from possible species differences, the existence of a non-CFTR, cAMP-activated channel in the apical membrane of the secretory cells would be surprising since glands from excised CF airways secrete no liquid when exposed to forskolin; therefore, all liquid that is induced by this agonist likely depends upon the presence of functional CFTR.
Because forskolin is a direct activator of adenylyl cyclase, we expected that the secretion response to this agonist would be a purely cAMP-dependent response. However, our observation that the forskolin-induced secretion response is dependent upon bath Ca 2ϩ challenges this notion. The identity of the Ca 2ϩ -dependent element in this signal transduction cascade is currently unknown, but several possibilities exist. Populations of apical membrane anion channels, basolateral membrane K ϩ channels, or intracellular kinases might be directly activated by increases in intracellular Ca 2ϩ concentration, or they may be secondarily activated or regulated by calmodulin. Additional studies will be needed to resolve this issue.
In the present study, HCO 3 Ϫ concentrations in the airway liquid samples were measured as a means for assessing the role of this anion in the liquid secretion process. We found that the airway epithelial barrier could not maintain large concentration gradients for HCO 3 Ϫ over the period of our experimental protocol. Because the directional changes in luminal HCO 3 Ϫ concentrations appeared to mirror the HCO 3 Ϫ concentration gradients imposed across the airway wall, we expect that these changes were due in large in part to partial equilibration of this anion across the surface epithelium of the airways. Indeed, sheep tracheal epithelium is sufficiently permeable to Cl Ϫ to permit a similar magnitude of anion efflux (see APPENDIX); thus the HCO 3 Ϫ "leak" that we see in the present study could be explained simply if the airway epithelial barrier were similarly permeable to Cl Ϫ and HCO 3 Ϫ . Alternatively, it is possible that a fraction of the loss of HCO 3 Ϫ from the 150 mM HCO 3 Ϫ instillate was due to the secretion of acid. Inglis et al. (10) reported that isolated perfused porcine bronchi secrete acid equivalents by a bafilomycin A 1 -sensitive process that is induced by luminal alkalinity. Regardless of the mechanism, this finding in the present study accounts for our previous observations with other secretion agonists where HCO 3 Ϫ concentrations in airway liquid were lower than expected following inhibition of Cl Ϫ secretion with bumetanide (3, 30) . Thus the luminal liquid HCO 3 Ϫ concentrations that are reported here must be recognized to be the consequence of both the primary glandular secretory processes and the secondary surface epithelial processes (i.e., transepithelial equilibration perhaps influenced by acid secretion). Because significant differences in HCO 3 Ϫ concentrations were observed between inhibitor treatments and their paired controls and because the changes trended in predictable directions, we believe that the HCO 3 Ϫ concentrations in airway liquid provide useful interpretive information. However, it is clear that these data should be judged cautiously.
Several similarities were found between the mechanism of forskolin-induced secretion and those previously reported for acetylcholine and substance P in these bronchi. All three secretagogues exhibit NKCC-dependent Cl Ϫ secretion, and, in the presence of bumetanide, NHE-dependent HCO 3 Ϫ secretion is observable (3, 29, 30) . Furthermore, the J v response is sensitive to NPPB, DPC, and glibenclamide (3, 29) . These results indicate that cAMP-mediated secretion utilizes several components common to acetylcholine-and substance P-dependent secretion. In contrast to our previous studies with acetylcholine and substance P, we noted a significant DIDS-sensitive component in forskolin-induced secretion (3, 29) . As discussed above, the target for this agent is unclear, but we speculate that DIDS inhibits a basolateral membrane HCO 3 Ϫ cotransporter such as NBC or NDAE.
In conclusion, we report that forskolin induces liquid secretion from the submucosal glands of porcine bronchial airways through induction of Cl Ϫ and HCO 3 Ϫ secretion. We note several important similarities between this process and muscarinic-induced liquid secretion including participation of NKCC and NHE as respective mediators of Cl Ϫ and HCO 3 Ϫ secretion. One noticeable difference was a prominent effect of DIDS, which blocks a component of HCO 3 Ϫ secretion. Because forskolin is likely to have induced secretion through elevation of intracellular cAMP, we speculate that CFTR serves as the anion efflux pathway across the apical membrane of the glandular secretory cells.
APPENDIX
This exercise was undertaken to determine whether the magnitude of HCO 3 Ϫ efflux across porcine cannulated bronchi was to be expected based upon known physiological properties of native, intact airway epithelia. While we are unaware of published values for HCO 3 Ϫ permeability for airway epithelia, Cl Ϫ permeability (PCl) of sheep tracheal epithelium has been reported by Olver and Robinson (20) to be 0.0000028 cm/s. We used this value to estimate the rate of Cl The total quantity of Cl Ϫ that leaves the luminal compartment, accounting for the mean airway surface area (3.6 cm 2 ) and period of exposure (127.5 min), would be 9.6 eq. This quantity is similar to the mean total HCO 3 Ϫ that is lost from the luminal solutions in the 150 meq/l HCO 3 Ϫ instillate experiments described in the present study (12.1 eq). Thus the magnitude of the HCO 3 Ϫ leak from the luminal compartment could be explained simply if the HCO 3 Ϫ permeability of porcine bronchi is similar to the Cl Ϫ permeability of sheep trachea. We acknowledge that these calculations are not ideal, since we do not account for changes in the anionic gradient that occur during the course of the experiment, the magnitude of solute back flux, or solvent drag (convective flow); rather, these values are idealized estimates since this study was not designed to rigorously measure permeability.
